Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cunox vs Botox for Glabellar Lines
NCT03837561Phase 3Completed
- Sponsor
- Medytox Inc.
- Start
- Dec 2018
- Primary completion
- Mar 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of neuronox in glabellar lines (2 arms), sponsored by Medytox Inc. Primary endpoint: Glabellar line improvement rate at maximum frown at 4 weeks. Started Dec 2018; status: completed.
02
Drugs
neuronox
03
Conditions
glabellar lines
Beyond the preview
Go deeper on NCT03837561.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03837561.